NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
*New Patient Story* ‘That Fraudulent Feeling’ by Simon
In a candid and inspiring update, Simon Walsh, a Neuroendocrine Cancer UK Ambassador, reflects on his pathway since his decision to retire early due to an unexpected cancer diagnosis. Simon, who was diagnosed with cancer two and a half years ago, questions the concept...
For members of our community living in Mid and South Essex: Have Your Say!
The NHS Mid and South Essex Integrated Care Board (ICB) is supporting Mid and South Essex NHS Foundation Trust (MSEFT) in its work to improve how people hear about hospital appointments and ongoing treatment. NHS Mid and South Essex Integrated Care Board (ICB) is...
Rapid Response to Neuroendocrine Cancer UK Community Reported Creon®️ Shortage : August 2023
Neuroendocrine Cancer UK Community Reported Creon® Shortage : August 2023 For a number of people with Neuroendocrine Cancer - pancreatic enzyme replacement therapy (PERT) is an essential part of daily life - taken to promote and maintain nutritional uptake and manage...